TANC2

TANC2 is a postsynaptic scaffolding/adaptor protein that organizes excitatory synapse function and constrains growth signaling during neurodevelopment, with loss-of-function mutations causing a neurodevelopmental syndrome (PMID:31616000, PMID:33976205). At dendritic spines it serves as a postsynaptic capture site for KIF1A-transported dense core vesicles, binding KIF1A directly without being part of the motor-cargo complex; patient-derived TANC2 mutations abolish this interaction (PMID:30021165), and TANC2 additionally engages multiple postsynaptic density proteins required for normal synaptic function (PMID:31616000). A central regulatory role is its direct binding to and inhibition of mTOR, suppressing both mTORC1 and mTORC2 in neurons and human neural progenitors; Tanc2 haploinsufficiency produces mTORC1/2 hyperactivity with synaptic and behavioral deficits that are reversed by rapamycin, and mTOR-activating stimuli such as serum or ketamine relieve this inhibition, positioning TANC2 as a stage-specific brake on mTOR signaling (PMID:33976205). Consistent with a role in balancing neuronal proliferation versus differentiation, tanc2 knockout in zebrafish expands the glutamatergic neuron population, promotes proliferation, and enlarges brain size, producing excitatory/inhibitory imbalance (PMID:36534563). Outside the nervous system, TANC2 is a SNX27 interactor routed toward lysosomal degradation, a process blocked by HPV-18 E6 oncoprotein in a PDZ-binding-motif-dependent manner to elevate TANC2 levels and enhance proliferation (PMID:36326272), and TANC2 is required for proliferation and survival of breast cancer cells harboring 17q23 amplification (PMID:24148822).

1. 2013 Medium

   Before any molecular role was assigned, it was unknown whether TANC2 was functionally important rather than a passenger in the recurrently amplified 17q23 locus; knockdown established it as a driver required for cancer cell proliferation and survival.

   Evidence siRNA knockdown in 17q23-amplified breast cancer cell lines with viability, apoptosis, and soft-agar colony assays

   PMID:24148822

   Open questions at the time

   • No molecular pathway placement beyond cell cycle arrest and apoptosis
   • Direct effectors of the proliferative phenotype not identified
2. 2018 Medium

   It was unclear how dense core vesicles are captured postsynaptically; TANC2 was shown to act as a spine capture site for KIF1A-transported DCVs, linking it physically to neuronal cargo trafficking and to neuropsychiatric disease mutations.

   Evidence KIF1A interactome proteomics, co-IP, live imaging of DCV transport, and mutant TANC2 interaction assays

   PMID:30021165

   Open questions at the time

   • Mechanism of vesicle tethering/release downstream of capture not resolved
   • TANC2 is not part of the motor-cargo complex, so the recruitment logic at spines is incomplete
3. 2019 Medium

   The synaptic function of TANC2 and its disease relevance were established by linking it to multiple PSD proteins and to a neurodevelopmental syndrome, framing it as a postsynaptic scaffold.

   Evidence Patient mutation analysis, PSD protein interaction studies, and Drosophila (rols ortholog) genetic disruption with behavioral readout

   PMID:31616000

   Open questions at the time

   • Identity and stoichiometry of the PSD interaction network not fully defined
   • Glial-cell phenotype in Drosophila not mechanistically connected to mammalian postsynaptic role
4. 2021 High

   The key signaling mechanism was unknown until TANC2 was shown to directly bind and inhibit mTOR, suppressing both mTORC1 and mTORC2 and acting as a developmentally staged brake on growth signaling whose loss causes rapamycin-reversible deficits.

   Evidence Co-IP of Tanc2-mTOR, Tanc2-null and haploinsufficient mouse models with rapamycin rescue, human neural progenitor assays, and biochemical mTORC1/2 activity measurements

   PMID:33976205

   Open questions at the time

   • Structural basis for simultaneous mTORC1/2 inhibition not defined
   • Molecular mechanism by which serum/ketamine relieves TANC2 inhibition unresolved
5. 2022 Medium

   How TANC2 abundance is controlled, and how a viral oncoprotein hijacks it, was addressed by identifying SNX27-directed lysosomal degradation of TANC2 that HPV-18 E6 blocks via the PDZ-binding motif to raise TANC2 levels and drive proliferation.

   Evidence GFP-IP mass spectrometry, co-IP, E6AP siRNA knockdown, and PBM-dependent proliferation assays

   PMID:36326272

   Open questions at the time

   • Connection between elevated TANC2 and the proliferation mechanism not detailed
   • Whether SNX27-mediated turnover operates in neurons is untested
6. 2022 Medium

   The cellular consequences of TANC2 loss in vivo for neuronal identity were clarified by showing zebrafish knockout selectively expands glutamatergic neurons and enlarges brain via increased proliferation and reduced apoptosis, producing E/I imbalance.

   Evidence CRISPR/Cas9 tanc2 knockout in zebrafish with neuronal marker quantification, proliferation/apoptosis, and behavioral assays

   PMID:36534563

   Open questions at the time

   • Mechanistic link between TANC2 loss and glutamatergic-specific expansion not established
   • Relationship to mTOR hyperactivity not directly tested in this model
7. 2022 Low

   Beyond the brain, a homozygous-viable mouse model implicated TANC2 in Hippo-pathway-associated developmental signaling and hepatic metabolism, indicating pleiotropic systemic roles.

   Evidence Tanc2-disrupted mouse with multi-systemic phenotyping and integrative analysis identifying Hippo pathway protein interactions

   PMID:34964047

   Open questions at the time

   • Hippo pathway interaction inferred from integrative analysis without direct biochemical validation
   • Causal link between TANC2 and liver dysfunction not established

• How TANC2's postsynaptic scaffolding, KIF1A-dependent vesicle capture, and direct mTORC1/2 inhibition are mechanistically integrated into a single regulatory hub at the spine remains unresolved.
• No structural model of TANC2 bound to mTOR or KIF1A
• Whether mTOR inhibition and DCV capture occur in the same spine compartment is unknown